AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05142631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.
Study NCT05044078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocal Inhibition MET
Description: If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
Study NCT05106816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin surface vibration
Description: This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.
Study NCT05106816 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: light skin surface vibration- SHAM
Description: This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
Study NCT05353842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WOWii Program
Description: Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
Study NCT05411783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tie of IMV
Description: The IMV will be tie under the left colic vein
Study NCT05549713 — intervention group
Intervention type: PROCEDURE
Intervention: Upper blepharoplasty
Description: Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
Study NCT05294016 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BRA CONNECT device
Description: skin thermal analysis for the detection of breast abnormalities
Study NCT04927741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Marjoram Essential Oil
Description: Subjects will receive a dilution of sweet marjoram essential oil (15 cc of grapeseed oil with 10 drops of sweet marjoram essential oil).~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping.
Study NCT04927741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapeseed Oil
Description: Subjects will receive 15 cc of undiluted grapeseed oil.~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping.
Study NCT05429125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube with Stylet
Description: Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.
Study NCT05429125 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Tip Bougie
Description: Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
Study NCT05800665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7656594
Description: RO7656594 will be administered orally at specified dose on specified days.
Study NCT06095128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusions
Study NCT06095128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib Tablets
Study NCT06538675 — intervention group
Intervention type: OTHER
Intervention: Psychotherapy
Description: Patients are assigned to a therapist and will receive psychotherapy
Study NCT05856786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Posterior segment OCT (a non-contact procedure performed over one minute) is additionally performed for patients participating in this study. Proportion of change in measurements in microns will be analyzed.
Study NCT03921515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blister induction
Description: Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
Study NCT03921515 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsies
Description: The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
Study NCT06644573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROSOMNIA Sleep Therapy™ (PSTx)
Description: PROSOMNIA Sleep Therapy (PSTx) is a novel intervention designed to manage homeostatic sleep pressure by leveraging an anesthesia-induced protocol. Using Diprivan/Propofol, PSTx rapidly induces REM sleep, clearing adenosine from the brain and reducing sleep pressure more efficiently than traditional methods. Monitored in real-time via EEG, this therapy personalizes sleep architecture optimization, ensuring deep restorative REM sleep. PSTx stands apart as a promising treatment for chronic insomnia, sleep deprivation, and REM sleep disorders, offering long-term improvement in sleep quality and overall health.
Study NCT06644573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia-Induced Sleep Therapy
Description: 1. Single-Arm, Non-Randomized Design: All eligible participants receive the same treatment PROSOMNIA Sleep Therapy(PSTx), ensuring consistency and homogeneity.~2. Targeted Use of Diprivan/Propofol: The PSTx involves the administration of Diprivan/Propofol, an FDA-approved anesthetic, delivered in a controlled environment under the supervision of an Anesthesiologist.~3. Monitored Anesthesia with Advanced Sleep Assessment: The procedure is monitored according to ASA (American Society of Anesthesiologists) standards, along with real-time EEG to track brain activity during REM sleep.~4. One (1) Hour PPSTx (60-120 minutes): A PSTx is designed to provide immediate results within a controlled timeframe of 60 to 120 minutes.~5. Follow-Up Protocol: Post-treatment follow-ups occur at 24 hours, 7 days, and 30 days after the session to measure outcomes and safety parameters.~6. Focus on Safety and Feasibility: A single-arm approach allows for a concentrated assessment of treatment efficacy.
Study NCT06644573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprivan (propofol), Astra-Zeneca
Description: Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.
Study NCT06644573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous EEG Monitoring
Description: Continuous EEG Monitoring is an essential component of PROSOMNIA Sleep Therapy, used to accurately track and optimize sleep architecture in real time. This device provides precise monitoring of brainwave activity, ensuring the patient achieves the necessary stages of REM sleep during therapy. Unlike other monitoring systems, this EEG is used to dynamically adjust the Diprivan/Propofol infusion, allowing for personalized sleep regulation. The continuous data collection helps maintain ideal sleep conditions, distinguishing it from standard sleep therapy interventions that lack real-time neurological insights.
Study NCT05217134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPEA
Description: Dural puncture with 27 G Whitacre needle
Study NCT06294184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tdcs lDLPFC
Description: The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3, cathode is on the FP2.
Study NCT06294184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tdcs rVLPFC
Description: The current is 2mA, duration is 1200s, fade in 30s, fade out 30s, anode is on the F6, cathode is on the FP1.
Study NCT06294184 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The current only persist in the fisrt 30s, duration is 1200s, fade in 30s, fade out 30s, anode is on the F3/F6, cathode is on the FP2/1.
Study NCT06008717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active subthalamic nucleus deep brain stimulation plus optimal drug therapy
Description: active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
Study NCT06008717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
Description: optimal drug therapy alone with DBS device turned off
Study NCT06002165 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: All clinics in North Carolina Perinatal Region IV have access to Severe HTN Bundle resources on the AIM website (https://saferbirth.org/psbs/severe-hypertension-in-pregnancy) and the locally adapted Outpatient HTN Bundle resources on the North Carolina Perinatal Region IV Provider Support Network website (https://www.mombaby.org/outpatient-bundle-for-severe-hypertension/). At baseline, the clinical leadership of all enrolled sites will receive direct communication via email that describes and provides links to the available resources. This will constitute usual care.
Study NCT06002165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACHIEVE Multi-component Implementation Strategy
Description: The intervention is comprised of four implementation strategies: facilitation/coaching, training, simulation, and delivering educational materials. The ACHIEVE study team, primarily the Nurse Coordinator, will engage teams within each clinic to participate in quality improvement activities utilizing these four strategies. The Nurse Coordinator will train the providers/staff on the O-HTN bundle components, facilitate corresponding office systems and workflow changes, and conduct simulations of patients with severe hypertension so care teams can practice the steps involved in recognizing and responding to episodes of severe hypertension in a timely manner.
Study NCT06384183 — intervention group
Intervention type: DEVICE
Intervention: Kerecis Fish Skin Graft
Description: Patients already treated with a Kerecis device
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVZO-021
Description: AVZO-021 is a selective and potent oral inhibitor of CDK2 being developed for the treatment of patients with advanced solid tumors with CDK2 dependency (1A), CCNE1 amplified solid tumors (2A), HR+/HER2- BC (1B1-1B5, 2B1-2B5) and CCNE1 amplified EOC (1C, 2C)
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Antineoplastic agent, cyclin-dependent kinase 4/6 inhibitor
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Antineoplastic agent, estrogen receptor antagonist
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Antineoplastic agent, aromatase inhibitor
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Antineoplastic CDK4/6 inhibitor
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Antineoplastic CDK4/6 inhibitor
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Alkylating agent
Study NCT05867251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Trop-2 antibody and topoisomerase inhibitor
Study NCT05347667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise Leg
Description: One leg will perform unilateral resistance exercise
Study NCT05347667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Leg
Description: One leg will serve as a non-exercise control
Study NCT05935215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: Open Label
Study NCT06405581 — intervention group
Intervention type: OTHER
Intervention: Edmonton frailty scale calculation
Description: The frailty status of the patients will be assessed using the Edmonton frailty scale.~According to the Edmonton frailty scale;~* (0-5): not frail~* (6-7): sensitive~* (8-9): slightly fragile~* (10-11): moderately fragile,~* (12-17): extremely fragile
Study NCT06351358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra treatment
Description: Subjects will receive treatment of Sculptra at baseline. Subjects will receive a second treatment of Sculptra at Week 4 visit. At the Week 8 visit, subjects will receive an optional treatment of Sculptra.
Study NCT06351358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Treatment
Description: Subjects will receive treatment Restylane Lyft or Restylane Contour at baseline. Subjects will receive an optional touch-up of Restylane Lyft or Restylane Contour at Week 4 visit.
Study NCT04778033 — intervention group
Intervention type: OTHER
Intervention: Sperm collection
Description: Those recruited will supply a single sperm sample 1-2 months following the second dose of the vaccination. The sample will be analyzed for macroscopic and microscopic features in the IVF laboratory and will be discarded immediately afterwards.
Study NCT05022030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mCapOX plus cetuximab
Description: capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w
Study NCT05022030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 plus cetuximab
Description: oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w
Study NCT04244032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: Participants complete up to 12 sessions of computerized training (30-45 min each) in a working memory task designed to utilize individually-adapted difficulty levels.
Study NCT04244032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibitory Control Training
Description: Participants complete up to 12 sessions of computerized training (30-45 min each) in an inhibitory control task designed to utilize individually-adapted difficulty levels.
Study NCT04244032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bias Modification Training
Description: Participants complete up to 12 sessions of computerized training (30-45 min each) in a bias modification task designed to utilize individually-adapted difficulty levels.
Study NCT06332378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 1 :Ball training
Description: Ball training Training in sitting position (the participants sat on the ball and did the exercises): holding balance position on the ball, active movements (flexion, extension, abduction, adduction) of one upper extremity, active movement of two upper extremities, trunk movements (bending forward and rotation), raising heel, raising toes, raising heel and toes simultaneously, resistance against perturbation, and weight shifting on ball and 2-Training in standing position: moving the ball up and down in a straight line with two upper extremities, moving the ball up and down in an oblique line with two upper extremities, moving the ball forward and backward with left and right lower extremities, moving the ball laterally with left and right lower extremities, throwing the ball against the wall with hand, throwing the ball against the wall with foot
Study NCT06332378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group 2 :Frenkel Exercises
Description: Frenkel Exercises Supine position~1. Flex and extend one leg, heel sliding down a straight line on table.~2. Abduct and adduct leg with knee and hip extended, leg sliding on table. Sitting position~1. Place foot on therapist's hand, which will change position. 2. Raise leg and put foot on traced footprint on the wall. 3. Rise and sit with knees together. Standing position~1. Place foot forward and backward on a straight line.~2. Walk along a winding strip.~3. Walk between two parallel lines
Study NCT06332378 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: By using random allocation, the participants will divided into three groups: an intervention group (N=30) that receive ball training exercise, another intervention group (N=30) that receive Frenkel training exercise and a control group (N=30
Study NCT05265546 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: The effects of different doses of psilocybin (0 - 14 mg) will be compared.
Study NCT05265546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The effects of different doses of psilocybin (0 - 14 mg) will be compared.
Study NCT06338085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional liberation technique
Description: In this intervention, with the technique taught by the researcher, women will self-administer the practice of lightly touching certain points 5 days and 1 time per week for 8 weeks. A whatsup group will be created by the researcher. A reminder message will be sent from this group to do the practice 1 time every day.
Study NCT05922462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greek yogurt
Description: For 16 weeks, athletes will consume 2 servings/day of 175 g GY (0% MF, flavoured, 130 calories, 17 g protein, 225 g calcium; e.g., OIKOS High Protein GY)
Study NCT05922462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: For 16 weeks, athletes will consume 2 servings/day of 2/3 of a scoop of commercially available WP powder (flavoured, \~29 g, 120 calories, 19 g protein, 112.5 g calcium; e.g., PURE Whey Protein, Walmart)
Study NCT06524648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: niPGT-A
Description: Embryos will be cultured, from oocyte fertilization up to day 6/7 of development, in a time lapse system following the standard practice. On day 6/7, embryos will be vitrified and the embryos's media will be collected for niPGT-A analysis.~Patients will undergo a single embryo transfer (SET) following the niPGT-A report indications. In the event of 1 or more embryos with the same niPGT-A score, the embryo for transfer will be determined by the site standard practice (morphology or time-lapse score).~Patients who do not achieve a pregnancy after a niPGT-A guided SET can undergo as many niPGT-A guided SET or COS+niPGT-A cycles as they need to get pregnant, while the study recruitment phase is active.
Study NCT06164392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Intravenous administration of indocyanine green followed by fluorescence angiography imaging of the neuroma
Study NCT06575023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tamponade of lower uterine segment in management of placenta accreta spectrum cases
Description: To compare the efficacy of lower uterine tamponade and partial lower myometrial resection in the management of intraoperative bleeding in cases with placenta accreta spectrum
Study NCT06575023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: partial myometrial resection of lower uterine segment in management of placenta accreta spectrum cases
Description: tamponade vs partial myomertial resection of lower uterine segment in managment of placenta accreta spectrum cases
Study NCT06063070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib Capsules
Description: oral
Study NCT06063070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Injectable solution
Study NCT04575051 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consult Model
Description: The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.
Study NCT04575051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consult Model
Description: The Consult Model (i.e., usual care) is an acute care strategy, relying on a monthly Audiologist visit to the facility.